Physiomics Plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PYC.L research report →
Companywww.physiomics.co.uk
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union. It offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. The company also develops technology for use in the field of personalized medicine.
- CEO
- Peter Joseph Sargent
- IPO
- 2004
- Employees
- 11
- HQ
- Oxford, GB
Price Chart
Valuation
- Market Cap
- $2.18M
- P/E
- -4.06
- P/S
- 2.29
- P/B
- 5.01
- EV/EBITDA
- -3.48
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -56.99%
- Op Margin
- -56.75%
- Net Margin
- -50.92%
- ROE
- -89.43%
- ROIC
- -137.35%
Growth & Income
- Revenue
- $784.00K · 44.32%
- Net Income
- $-415,254 · 31.85%
- EPS
- $-0.00 · 62.22%
- Op Income
- $-457,791
- FCF YoY
- 2.72%
Performance & Tape
- 52W High
- $0.80
- 52W Low
- $0.25
- 50D MA
- $0.49
- 200D MA
- $0.43
- Beta
- 0.95
- Avg Volume
- 6.43M
Get TickerSpark's AI analysis on PYC.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PYC.L Coverage
We haven't published any research on PYC.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PYC.L Report →